ArticleResuscitation plus2025
Impact of extended eligibility criteria on survival after veno-arterial extracorporeal membrane oxygenation for refractory cardiac arrest: a 8-year single-center study.
Article in Resuscitation plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) may improve survival in refractory in- or out-of-hospital cardiac arrest (IHCA/OHCA), yet optimal selection criteria remain uncertain. We aimed to report contemporary survival rates after VA-ECMO for cardiac arrest (E-CPR) and to explore prognostic significance of extended criteria in improving patient selection. Methods: We conducted an observational single-center study of patients treated with E-CPR from 2017 to 2024. Patients were stratified according to four extended inclusion criteria in favor of E-CPR (arterial pH > 6.8, lactate < 15 mmol/L, low-flow time < 100 min, signs of life during CPR). Primary outcome was 180-day survival. Results: Of 159 patients included, 59 (37 %) were alive at 180 days, and 82 % of survivors had favorable neurological outcomes. Transient ROSC (OR 0.25, 95 % CI 0.13-0.49) and signs of life during CPR (OR 0.37, 95 % CI 0.19-0.75) were associated with lower mortality in univariate analysis. In multivariate analysis, only age (OR 1.03, 95 % CI 1.00-1.06) and transient ROSC (OR 0.25, 95 % CI 0.11-0.56) remained independently associated with 180-day mortality. Kaplan-Meier survival analysis showed significant differences between groups (log-rank Conclusion: In this single-center cohort, we observed a 180-day survival rate of 38 % among patients treated with E-CPR for refractory cardiac arrest. Notably, our study suggests acceptable survival rates of 21 % even in patients with an adverse risk profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.